Viyash Scientific growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+120.6%+34.0%
EBITDA+303.7%+279.2%
Net Income+597.3%—
EPS (adj.)+711.4%—
Total Assets+189.1%+44.6%
Total Equity+304.7%+60.8%
Free Cash Flow+325.5%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VIYASH₹224.55

Viyash Scientific Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSYATHARTHTHYROCARESUPRIYASTARSPARCSHILPAMEDRUBICONMcap ₹9,809 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+120.6+34.0
EBITDA+303.7+279.2
Net Income+597.3—
EPS (adj.)+711.4—
Total Assets+189.1+44.6
Total Equity+304.7+60.8
Free Cash Flow+325.5—
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.